Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Firefly Neuroscience (AIFF) EBITDA Margin (2016 - 2025)

Firefly Neuroscience has reported EBITDA Margin over the past 15 years, most recently at 607.04% for Q4 2025.

  • Quarterly results put EBITDA Margin at 607.04% for Q4 2025, up 587598.0% from a year ago — trailing twelve months through Dec 2025 was 775.48% (up 853007.0% YoY), and the annual figure for FY2025 was 775.48%, up 853378.0%.
  • EBITDA Margin for Q4 2025 was 607.04% at Firefly Neuroscience, up from 684.54% in the prior quarter.
  • Over the last five years, EBITDA Margin for AIFF hit a ceiling of 24.36% in Q2 2023 and a floor of 12921.21% in Q3 2024.
  • Median EBITDA Margin over the past 5 years was 203.81% (2022), compared with a mean of 2688.6%.
  • Biggest five-year swings in EBITDA Margin: plummeted -1261436bps in 2024 and later surged 1223668bps in 2025.
  • Firefly Neuroscience's EBITDA Margin stood at 2.22% in 2021, then tumbled by -2213bps to 51.38% in 2022, then crashed by -222bps to 165.55% in 2023, then crashed by -3816bps to 6483.02% in 2024, then skyrocketed by 91bps to 607.04% in 2025.
  • The last three reported values for EBITDA Margin were 607.04% (Q4 2025), 684.54% (Q3 2025), and 546.49% (Q2 2025) per Business Quant data.